{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:11:07Z","timestamp":1788012667212,"version":"build-2784847793"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR130580"],"award-info":[{"award-number":["NIHR130580"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,1,30]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3\u2009monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping monitoring after 1 year. To rationalise monitoring, we developed and validated a prognostic model for clinically significant blood, liver or kidney toxicity during established sulfasalazine treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>UK primary care. Data from Clinical Practice Research Datalink Gold and Aurum formed independent development and validation cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Age \u226518 years, new diagnosis of an inflammatory condition and sulfasalazine prescription.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study period<\/jats:title>\n                  <jats:p>1 January 2007 to 31 December 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome<\/jats:title>\n                  <jats:p>Sulfasalazine discontinuation with abnormal monitoring blood-test result.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Analysis<\/jats:title>\n                  <jats:p>Patients were followed up from 6\u2009months after first primary care prescription to the earliest of outcome, drug discontinuation, death, 5 years or 31 December 2019. Penalised Cox regression was performed to develop the risk equation. Multiple imputation handled missing predictor data. Model performance was assessed in terms of calibration and discrimination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>8936 participants were included in the development cohort (473 events, 23\u2009299 person-years) and 5203 participants were included in the validation cohort (280 events, 12\u2009867 person-years). Nine candidate predictors were included. The optimism adjusted R<jats:sup>2<\/jats:sup>\n                     <jats:sub>D<\/jats:sub> and Royston D statistic in the development data were 0.13 and 0.79, respectively. The calibration slope (95% CI) and Royston D statistic (95% CI) in validation cohort was 1.19 (0.96 to 1.43) and 0.87 (0.67 to 1.07), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This prognostic model for sulfasalazine toxicity uses readily available data and should be used to risk-stratify blood-test monitoring during established sulfasalazine treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003980","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T21:00:12Z","timestamp":1709845212000},"page":"e003980","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"first","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Grainge","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-2250","authenticated-orcid":false,"given":"Tim","family":"Card","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham, Nottingham, UK"},{"name":"Centre for Evidence Based Dermatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W","family":"Taal","sequence":"additional","affiliation":[{"name":"Translational Medical Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P","family":"Aithal","sequence":"additional","affiliation":[{"name":"Translational Medical Sciences, University of Nottingham, Nottingham, UK"},{"name":"Nottingham NIHR BRC, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Fox","sequence":"additional","affiliation":[{"name":"Translational Medical Sciences, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D","family":"Mallen","sequence":"additional","affiliation":[{"name":"School of Meicine, Keele University, Keele, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Stevenson","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Nakafero","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riley","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2025090313340686000_10.1.e003980.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"2025090313340686000_10.1.e003980.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2022.03.005"},{"key":"2025090313340686000_10.1.e003980.3","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.536"},{"key":"2025090313340686000_10.1.e003980.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/28.2.134"},{"key":"2025090313340686000_10.1.e003980.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/28.2.175"},{"key":"2025090313340686000_10.1.e003980.6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.40","article-title":"Long-term usage and Side-effect profile of sulphasalazine in rheumatoid arthritis","volume":"XXXIV","author":"van Riel","year":"1995","journal-title":"Rheumatology"},{"key":"2025090313340686000_10.1.e003980.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02133.x"},{"key":"2025090313340686000_10.1.e003980.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6212.442"},{"key":"2025090313340686000_10.1.e003980.9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-198600321-00010","article-title":"Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine","volume":"32 Suppl 1","author":"Farr","year":"1986","journal-title":"Drugs"},{"key":"2025090313340686000_10.1.e003980.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6544.420"},{"key":"2025090313340686000_10.1.e003980.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.11.967"},{"key":"2025090313340686000_10.1.e003980.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.48.6.505"},{"key":"2025090313340686000_10.1.e003980.13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-9-48","article-title":"Et al.hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events.BMC","volume":"9","author":"Jobanputra","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090313340686000_10.1.e003980.14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02333012"},{"key":"2025090313340686000_10.1.e003980.15","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.45"},{"key":"2025090313340686000_10.1.e003980.16","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/94.6.309"},{"key":"2025090313340686000_10.1.e003980.17","unstructured":"Committee JF . British national Formulary.[85]. London BMJ Group and Pharmaceutical Press; 2023."},{"key":"2025090313340686000_10.1.e003980.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew479"},{"key":"2025090313340686000_10.1.e003980.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313340686000_10.1.e003980.20","unstructured":"Pfizer . Salazopyrin tablets. Healthcare professionals (Smpc) 2021. 2021. Available: https:\/\/www.medicines.org.uk\/emc\/product\/3838\/smpc#gref [Accessed 23 Jul 2023]."},{"key":"2025090313340686000_10.1.e003980.21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025090313340686000_10.1.e003980.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025090313340686000_10.1.e003980.23","first-page":"736","article-title":"Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313340686000_10.1.e003980.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074678","article-title":"Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK","volume":"381","author":"Nakafero","year":"2023","journal-title":"BMJ"},{"key":"2025090313340686000_10.1.e003980.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab254"},{"key":"2025090313340686000_10.1.e003980.26","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"2025090313340686000_10.1.e003980.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.001"},{"key":"2025090313340686000_10.1.e003980.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200213"},{"key":"2025090313340686000_10.1.e003980.29","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198510040-00001"},{"key":"2025090313340686000_10.1.e003980.30","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000414"},{"key":"2025090313340686000_10.1.e003980.31","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2136-8"},{"key":"2025090313340686000_10.1.e003980.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"2025090313340686000_10.1.e003980.33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9025"},{"key":"2025090313340686000_10.1.e003980.34","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800102"},{"key":"2025090313340686000_10.1.e003980.35","unstructured":"Steyerberg EW . Clinical prediction models: A practical approach to development, validation, and updating. Cham, SWITZERLAND Springer International Publishing AG; 2019."},{"key":"2025090313340686000_10.1.e003980.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025090313340686000_10.1.e003980.37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/01621459.1957.10501411","article-title":"Note on grouping","volume":"52","author":"Cox","year":"1957","journal-title":"JASA"},{"key":"2025090313340686000_10.1.e003980.38","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0698"},{"key":"2025090313340686000_10.1.e003980.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05838.x"},{"key":"2025090313340686000_10.1.e003980.40","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkad053","article-title":"Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)","volume":"7","author":"Mielnik","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"2025090313340686000_10.1.e003980.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203084","article-title":"Non-alcoholic Steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent Transaminitis during low-dose methotrexate treatment","volume":"13","author":"Mori","year":"2018","journal-title":"PLoS One"},{"key":"2025090313340686000_10.1.e003980.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab790"},{"key":"2025090313340686000_10.1.e003980.43","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2022-0074"},{"key":"2025090313340686000_10.1.e003980.44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab917"},{"key":"2025090313340686000_10.1.e003980.45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14397595.2020.1823604","article-title":"Post-marketing surveillance of high-dose methotrexate (>8 mg\/week) in Japanese patients with rheumatoid arthritis: a post hoc sub-analysis of patients according to duration of prior methotrexate use","volume":"31","author":"Suzuki","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025090313340686000_10.1.e003980.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.106617"},{"key":"2025090313340686000_10.1.e003980.47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.22294","article-title":"Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record","volume":"66","author":"Schmajuk","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313340686000_10.1.e003980.48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/acr.20037","article-title":"Neutropenia in patients receiving anti-tumor necrosis factor therapy","volume":"62","author":"Hastings","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:34:14Z","timestamp":1756931654000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/rmdopen-2023-003980"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003980","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}